European Journal of Cancer
Volume 46, Issue 2 , Pages 395-404 , January 2010

New opportunities for drug outcomes research in cancer patients: The linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System

  • Myrthe P.P. van Herk-Sukel

      Affiliations

    • PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author: Address: PHARMO Institute for Drug Outcomes Research, P.O. Box 85222, 3508 AE Utrecht, The Netherlands. Tel.: +31 (0)30 2345 620; fax: +31 (0)30 2345 568.
    • ,
  • Lonneke V. van de Poll-Franse

      Affiliations

    • Eindhoven Cancer Registry, Comprehensive Cancer Center South, Eindhoven, The Netherlands
    • Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, The Netherlands
    • ,
  • Valery E.P.P. Lemmens

      Affiliations

    • Eindhoven Cancer Registry, Comprehensive Cancer Center South, Eindhoven, The Netherlands
    • Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands
    • ,
  • Gerard Vreugdenhil

      Affiliations

    • Department of Internal Medicine, Máxima Medical Centre, Veldhoven, The Netherlands
    • ,
  • Johannes F.M. Pruijt

      Affiliations

    • Department of Internal Medicine, Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands
    • ,
  • Jan Willem W. Coebergh

      Affiliations

    • Eindhoven Cancer Registry, Comprehensive Cancer Center South, Eindhoven, The Netherlands
    • Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands
    • ,
  • Ron M.C. Herings

      Affiliations

    • PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands
    • Department of Health Policy and Management, Erasmus University Medical Centre, Rotterdam, The Netherlands

Received 28 July 2009 ,Accepted 9 September 2009.

References 

  1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592
  2. Harpe SE. Using secondary data sources for pharmacoepidemiology and outcomes research. Pharmacotherapy. 2009;29:138–153
  3. Ladewski LA, Belknap SM, Nebeker JR, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol. 2003;21:3859–3866
  4. Viale PH, Moore S. Postmarketing surveillance for oncology drugs. Clin J Oncol Nurs. 2008;12:877–886
  5. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol. 2008;52:1141–1147
  6. Zhao YS, Zhu S, Li XW, et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat. 2009;117:141–150
  7. Ayanian JZ, Jacobsen PB. Enhancing research on cancer survivors. J Clin Oncol. 2006;24:5149–5153
  8. Schrag D. Enhancing cancer registry data to promote rational health system design. J Natl Cancer Inst. 2008;100:378–379
  9. Herings RMC. The PHARMO system. CNS Spectr. 2007;12:14–17
  10. Houterman S, Janssen-Heijnen ML, van de Poll-Franse LV, Brenner H, Coebergh JW. Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis. Ann Oncol. 2006;17:709–712
  11. Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognosis for long-term survivors of cancer. Ann Oncol. 2007;18:1408–1413
  12. Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands. Thesis [Doctorate]. Utrecht: Utrecht University; 1993.
  13. Herings RMC, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health. 1992;46:136–140
  14. Herings RMC, Stricker BH, Bakker A. Pharmaco-morbidity linking: a pilot study of its technical possibilities in The Netherlands. Ned Tijdschr Geneeskd. 1990;134:1903–1907
  15. Stricker BH, Herings RM, Bakker A, Valkenburg HA, Sturmans F. Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance. Ned Tijdschr Geneeskd. 1990;134:1886–1889
  16. Blakely T, Salmond C. Probabilistic record linkage and a method to calculate the positive predictive value. Int J Epidemiol. 2002;31:1246–1252
  17. Meray N, Reitsma JB, Ravelli AC, Bonsel GJ. Probabilistic record linkage is a valid and transparent tool to combine databases without a patient identification number. J Clin Epidemiol. 2007;60:883–891
  18. Newcombe HB. Handbook of record linkage: methods for health and statistical studies, administration, and business. Oxford: Oxford University Press; 1988;
  19. Howe GR. Use of computerized record linkage in cohort studies. Epidemiol Rev. 1998;20:112–121
  20. Fenna D. Phonetic reduction of names. Comput Programs Biomed. 1984;19:31–36
  21. The Good Conduct code [Code Goed Gedrag. Gedragscode Gezondheidsonderzoek]. Rotterdam: FMWV [Federation of Medical Research Associations]. <http://www.federa.org/>; 2005.
  22. Dal Maso L, Braga C, Franceschi S. Methodology used for “software for automated linkage in Italy” (SALI). J Biomed Inform. 2001;34:387–395
  23. Roos LL, Walld R, Wajda A, Bond R, Hartford K. Record linkage strategies, outpatient procedures, and administrative data. Med Care. 1996;34:570–582
  24. de Vries E, Louwman M, Bastiaens M, de Gruijl F, Coebergh JW. Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol. 2004;123:634–638
  25. Sukel MP, Breekveldt-Postma NS, Erkens JA, et al. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice. Pharmacoepidemiol Drug Saf. 2008;17:125–134

PII: S0959-8049(09)00682-0

doi: 10.1016/j.ejca.2009.09.010

European Journal of Cancer
Volume 46, Issue 2 , Pages 395-404 , January 2010

Article Tools

* Image Usage & Resolution